Oppenheimer & Close LLC lowered its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,581 shares of the biopharmaceutical company's stock after selling 7,445 shares during the quarter. Pfizer accounts for approximately 8.5% of Oppenheimer & Close LLC's holdings, making the stock its 2nd biggest holding. Oppenheimer & Close LLC's holdings in Pfizer were worth $7,475,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in PFE. Ullmann Wealth Partners Group LLC increased its position in Pfizer by 6.2% during the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company's stock worth $298,000 after purchasing an additional 335 shares in the last quarter. Red Door Wealth Management LLC increased its position in Pfizer by 8.6% during the 1st quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company's stock worth $5,675,000 after purchasing an additional 8,694 shares in the last quarter. Capital City Trust Co. FL increased its position in Pfizer by 49.9% during the 1st quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 2,816 shares in the last quarter. Colonial River Wealth Management LLC increased its position in Pfizer by 52.3% during the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company's stock worth $1,087,000 after purchasing an additional 7,206 shares in the last quarter. Finally, Annex Advisory Services LLC increased its position in Pfizer by 23.6% during the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 1,966 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company's stock.
Get Pfizer alerts:Pfizer Stock Performance
Pfizer stock opened at $44.08 on Friday. The stock's 50 day moving average price is $48.24 and its 200 day moving average price is $50.32. The firm has a market capitalization of $247.39 billion, a PE ratio of 8.63, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71.
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. The firm had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. Pfizer's revenue for the quarter was up 46.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.07 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 6.54 EPS for the current fiscal year.Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.63%. The ex-dividend date is Thursday, November 3rd. Pfizer's dividend payout ratio (DPR) is presently 31.31%.
Analysts Set New Price Targets
A number of analysts recently commented on the company. SVB Leerink dropped their price objective on Pfizer from $55.00 to $53.00 and set a "market perform" rating for the company in a research report on Friday, July 29th. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a report on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 price target on Pfizer in a report on Wednesday, September 14th. Finally, Barclays set a $50.00 price target on Pfizer in a report on Thursday, September 1st. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.00.
About Pfizer
(Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Featured Articles
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.